Cidofovir

Comprehensive Clinical Monograph: Cidofovir (Vistide)

1. Introduction and Overview

Cidofovir, commercially known as Vistide, is a potent, broad-spectrum acyclic nucleoside phosphonate analog of deoxycytidine. It serves as a cornerstone therapy in the management of specific, severe viral infections, most notably Cytomegalovirus (CMV) retinitis in patients with Acquired Immunodeficiency Syndrome (AIDS). Unlike traditional nucleoside analogs that require intracellular phosphorylation by viral enzymes, cidofovir is unique because it bypasses the initial rate-limiting phosphorylation step, making it highly effective against viral strains that have developed resistance to agents like ganciclovir or foscarnet.

Due to its significant nephrotoxic profile, the administration of cidofovir necessitates a strict clinical protocol involving pre-hydration with normal saline and the co-administration of probenecid to mitigate renal tubular damage. This guide provides a deep-dive into the pharmacology, clinical application, and rigorous safety parameters required for the administration of this high-alert medication.

2. Pharmacological Mechanism of Action

Cidofovir’s potency is derived from its ability to inhibit viral DNA polymerase, thereby halting the replication of the viral genome.

The Biochemical Pathway

1. Intracellular Activation: Once inside the host cell, cidofovir is converted into its active metabolite, cidofovir diphosphate, by host cellular kinases (specifically pyruvate kinase and nucleoside diphosphate kinase). Because it is already a phosphonate, it does not require the viral thymidine kinase or phosphotransferase, which is why it remains effective against CMV isolates that are resistant to ganciclovir.
2. Competitive Inhibition: The active metabolite, cidofovir diphosphate, acts as a competitive inhibitor of viral DNA polymerase. It competes with deoxycytidine triphosphate (dCTP) for incorporation into the growing viral DNA chain.
3. Chain Termination: Once incorporated, cidofovir diphosphate acts as a chain terminator. It causes a reduction in the rate of viral DNA synthesis, effectively preventing the virus from replicating and spreading to neighboring cells.
4. Prolonged Half-Life: A defining feature of cidofovir is its long intracellular half-life, allowing for infrequent dosing schedules compared to other antiviral agents.

3. Pharmacokinetics

Understanding the pharmacokinetic profile of cidofovir is essential for managing its narrow therapeutic index.

4. Clinical Indications and Dosage Guidelines

Cidofovir is FDA-approved for the treatment of CMV retinitis in patients with AIDS. However, its use has expanded in clinical practice under off-label protocols for other refractory viral conditions.

Approved Indication: CMV Retinitis

• Induction Phase: 5 mg/kg administered intravenously once weekly for two consecutive weeks.
• Maintenance Phase: 5 mg/kg administered intravenously once every two weeks.

Critical Administrative Protocol (Mandatory)

• Probenecid: Must be administered orally to reduce the risk of nephrotoxicity.
  • 2g administered 3 hours prior to the cidofovir dose.
  • 1g administered 2 hours and 8 hours after the completion of the 1-hour cidofovir infusion.
• Hydration: Patients must receive at least 1 liter of 0.9% normal saline intravenously over 1–2 hours immediately before the cidofovir infusion.

5. Risks, Side Effects, and Contraindications

Major Side Effects

• Nephrotoxicity: The most significant dose-limiting toxicity. Manifests as proteinuria, increased serum creatinine, and Fanconi-like syndrome.
• Neutropenia: A common hematologic adverse event; regular complete blood counts (CBC) are required.
• Ocular Hypotension: Potential for decreased intraocular pressure.
• Metabolic Acidosis: Secondary to proximal tubular dysfunction.

Contraindications

• Baseline Renal Impairment: Patients with a serum creatinine > 1.5 mg/dL or a creatinine clearance ≤ 55 mL/min.
• Probenecid Hypersensitivity: Patients who have a history of clinically significant hypersensitivity to probenecid or other sulfa-containing medications.
• Direct Intraocular Injection: Cidofovir is contraindicated for intravitreal injection due to the risk of severe ocular inflammation and hypotony.

6. Drug Interactions

The interaction profile of cidofovir is largely dominated by its nephrotoxic potential and its reliance on renal clearance.

1. Nephrotoxic Agents: Concurrent use of aminoglycosides, amphotericin B, foscarnet, intravenous pentamidine, or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided, as these significantly increase the risk of acute renal failure.
2. Probenecid Interactions: Since probenecid inhibits the secretion of various drugs, it may alter the pharmacokinetics of agents such as methotrexate, acyclovir, or penicillins. Monitor patients closely if these are co-administered.

7. Pregnancy, Lactation, and Pediatric Use

• Pregnancy (Category C): Animal studies have shown embryotoxicity and teratogenicity. Cidofovir should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
• Lactation: It is unknown whether cidofovir is excreted in human milk. Given the potential for serious adverse reactions in nursing infants, a decision must be made to either discontinue nursing or discontinue the drug.
• Pediatric Use: Safety and efficacy in pediatric patients have not been established. Use with extreme caution and only when the clinical necessity outweighs the risks.

8. Overdose Management

There is no specific antidote for cidofovir overdose.
* Management: In the event of an overdose, the infusion must be discontinued immediately.
* Renal Support: Hydration should be aggressively managed to promote diuresis and minimize tubular exposure.
* Hemodialysis: Hemodialysis may be considered to reduce plasma concentrations, although its efficacy in removing intracellular cidofovir is limited due to the drug’s long intracellular half-life.

9. Frequently Asked Questions (FAQ)

1. Why is probenecid required with cidofovir?
Probenecid blocks the active tubular secretion of cidofovir in the kidneys. By inhibiting this transport, it significantly reduces the concentration of the drug within the renal tubular cells, thereby lowering the risk of nephrotoxicity.

2. What should I monitor before each dose?
You must monitor serum creatinine and urine protein levels before every infusion. If creatinine increases by 0.3–0.4 mg/dL, the dose must be reduced or the treatment held.

3. Is cidofovir effective against HIV?
No. Cidofovir is a CMV-specific antiviral and has no direct activity against HIV. It is intended for HIV-positive patients suffering from opportunistic CMV infections.

4. Can cidofovir be given if a patient is allergic to sulfa drugs?
Probenecid is a sulfonamide derivative. Patients with a known hypersensitivity to sulfa drugs may be at risk for a cross-reaction and should generally avoid this combination.

5. What is the difference between cidofovir and ganciclovir?
Cidofovir does not require initial phosphorylation by viral kinases, allowing it to remain effective against viral strains that have become resistant to ganciclovir due to UL97 mutations.

6. How long does the protective effect of one dose last?
Due to the long intracellular half-life of the active metabolite, cidofovir is dosed only once every two weeks during the maintenance phase, providing prolonged viral suppression.

7. Is cidofovir used for skin warts?
Yes, off-label topical use of cidofovir has been investigated for recalcitrant human papillomavirus (HPV) infections, though this is not an FDA-approved indication.

8. What happens if a patient misses a dose of probenecid?
If the probenecid regimen is missed, the patient is at significantly higher risk for acute kidney injury. The cidofovir infusion should not be administered without proper probenecid coverage.

9. Does cidofovir cause hair loss?
Alopecia is not a commonly reported side effect, though patients undergoing systemic antiviral therapy may experience general fatigue or malaise.

10. How should the medication be stored?
Cidofovir injection should be stored at controlled room temperature (20°C to 25°C). It should not be frozen.

10. Clinical Summary for Healthcare Professionals

Cidofovir remains an indispensable tool in the therapeutic armamentarium against resistant CMV infections. Its clinical utility is defined by its unique phosphonate structure, which facilitates a bypass of viral resistance mechanisms. However, this clinical benefit is strictly tethered to the meticulous management of renal safety.

Healthcare providers must adhere to the following "Golden Rules" of administration:
1. Strict Renal Monitoring: Never administer if baseline renal function is compromised.
2. Hydration is Non-Negotiable: Ensure adequate volume expansion before infusion.
3. Probenecid Adherence: Ensure the patient understands the necessity of the 3-dose probenecid schedule.
4. Hematologic Surveillance: Monitor absolute neutrophil counts to prevent severe neutropenia.

By maintaining these high standards of clinical oversight, cidofovir can be utilized safely to provide life-altering control of CMV retinitis in immunocompromised populations.

DISCLAIMER: This document is for educational and clinical reference purposes only. It does not replace professional medical judgment, diagnosis, or treatment. Always consult the most current FDA-approved package insert and institutional pharmacy guidelines before administering any medication.